AFT Pharmaceuticals Valuation Multiples

AFT Pharmaceuticals Overview

About AFT Pharmaceuticals

AFT Pharmaceuticals Ltd is a pharmaceutical distributor and developer of pharmaceutical intellectual property. Some of the products of the organization are Maxigesic dose forms, Capsaicin creams, Crystaderm, Kiwisoothe, Micolette, and others. The group has four operating segments based on geographical location being Australia, New Zealand, Asia, and the Rest of the world. It generates the majority of the revenue from Australia, which includes the sales and distribution activity relating to the Australian market.

Founded

1997

HQ

Employees

119

Website

aftpharm.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $155M

EBITDA: $16M

EV

$237M

Valuation Multiples

Multiples.vc

Start free trial

AFT Pharmaceuticals Financials

AFT Pharmaceuticals reported last 12-month revenue of $155M and EBITDA of $16M.

In the same LTM period, AFT Pharmaceuticals generated $68M in gross profit, $16M in EBITDA, and $9M in net income.

AFT Pharmaceuticals P&L

In the most recent fiscal year, AFT Pharmaceuticals reported revenue of $123M and EBITDA of $13M.

AFT Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX

AFT Pharmaceuticals Stock Performance

AFT Pharmaceuticals has current market cap of $222M, and enterprise value of $237M.

AFT Pharmaceuticals' stock price is $2.11.

AFT Pharmaceuticals Valuation Multiples

AFT Pharmaceuticals trades at 1.5x EV/Revenue multiple, and 14.6x EV/EBITDA.

AFT Pharmaceuticals Financial Valuation Multiples

As of April 18, 2026, AFT Pharmaceuticals has market cap of $222M and EV of $237M.

Equity research analysts estimate AFT Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

AFT Pharmaceuticals has a P/E ratio of 23.7x.

AFT Pharmaceuticals Margins & Growth Rates

AFT Pharmaceuticals' revenue in the last 12 month grew by 16%.

AFT Pharmaceuticals' revenue per employee in the last FY averaged $1.0M, while opex per employee averaged $0.4M for the same period.

AFT Pharmaceuticals' rule of 40 is 29% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

AFT Pharmaceuticals' rule of X is 57% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

AFT Pharmaceuticals Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

AFT Pharmaceuticals M&A Activity

AFT Pharmaceuticals acquired XXX companies to date.

Last acquisition by AFT Pharmaceuticals was on XXXXXXXX, XXXXX. AFT Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

AFT Pharmaceuticals Investment Activity

AFT Pharmaceuticals invested in XXX companies to date.

AFT Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. AFT Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).